Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)

Overview

  • Product nameAnti-Met (c-Met) (phospho Y1349) antibody [EP2367Y]
    See all Met (c-Met) primary antibodies
  • Description
    Rabbit monoclonal [EP2367Y] to Met (c-Met) (phospho Y1349)
  • SpecificityThis antibody detects Met (c-Met) phosphorylated at tyrosine 1349.
  • Tested applicationsSuitable for: WB, IP, IHC-Pmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Met (c-Met).
    (Peptide available as ab175821)

  • Positive control
    • A431 cell lysate; human breast carcinoma tissue
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

     

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

    A trial size is available to purchase for this antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab68141 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/5000 - 1/10000. Predicted molecular weight: 156 kDa.
IP 1/20.
IHC-P 1/50 - 1/100.
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • DomainThe kinase domain is involved in SPSB1 binding.
    • Post-translational
      modifications
      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • AUTS9 antibody
      • c met antibody
      • D249 antibody
      • Hepatocyte growth factor receptor antibody
      • HGF antibody
      • HGF receptor antibody
      • HGF/SF receptor antibody
      • HGFR antibody
      • MET antibody
      • Met proto oncogene tyrosine kinase antibody
      • MET proto oncogene, receptor tyrosine kinase antibody
      • Met proto-oncogene (hepatocyte growth factor receptor) antibody
      • Met proto-oncogene antibody
      • Met protooncogene antibody
      • MET_HUMAN antibody
      • Oncogene MET antibody
      • Par4 antibody
      • Proto-oncogene c-Met antibody
      • RCCP2 antibody
      • Scatter factor receptor antibody
      • SF receptor antibody
      • Tyrosine-protein kinase Met antibody
      see all

    Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] images

    • Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab68141 at a dilution of 1/50.
    • All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/5000 dilution

      Lane 1 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h. Whole cell lysates
      Lane 2 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates
      Lane 3 : HeLa (Human cervix adenocarcinoma epithelial cell) serum starved for 24 h and then treated with hepatocyte growth factor at 40ng/ml for 5 min. Whole cell lysates. Then the membrane was incubated with phosphatase.

      Lysates/proteins at 15 µg per lane.

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution

      Predicted band size : 156 kDa
      Observed band size : 150 kDa (why is the actual band size different from the predicted?)


      Exposure time : 30 seconds

      Blocking and diluting buffer and concentration: 5% NFDM/TBST.

      The molecular weight of Met (c-Met) (phospho Y1349) and Met (c-Met) is different. Ab51067 could only recognize the pro-Met which is 190kDa, but ab68141 recognizes theβ-subunits which is 145kDa.

    • All lanes : Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141) at 1/10000 dilution

      Lane 1 : A431 cell lysate, untreated
      Lane 2 : A431 cell lysate, treated with AP

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP-labeled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 156 kDa
      Observed band size : ~150 kDa (why is the actual band size different from the predicted?)
    • Dot blot analysis of Met (c-Met) (phospho Y1349) phospho peptide (Lane 1), Met (c-Met) Non-phospho peptide (Lane 2), labelling Met (c-Met) (phospho Y1349) with ab68141 at a dilution of 1/1000. Peroxidase conjugated goat anti-rabbit IgG (H+L)) was used as the secondary antibody at a dilution of 1/2500.

      Blocking and diluting buffer: 5% NFDM/TBST.

      Exposure time: 3 minutes.

    References for Anti-Met (c-Met) (phospho Y1349) antibody [EP2367Y] (ab68141)

    This product has been referenced in:
    • Majumder B  et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun 6:6169 (2015). IHC-P ; Human . Read more (PubMed: 25721094) »
    • Gerdes MJ  et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 110:11982-7 (2013). ICC/IF ; Human . Read more (PubMed: 23818604) »

    See all 3 Publications for this product

    Product Wall

    Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
    Antigen retrieval step Heat mediated - Buffer/Enzyme Used: TRIS EDTA Buffer pH 9,0
    Sample Human Tissue sections (Breast Cancer)
    Specification Breast Cancer
    Permeabilization Yes - Wash Buffer from Dako with Tween
    Fixative Paraformaldehyde
    Username

    Mr. Rudolf Jung

    Verified customer

    Submitted Dec 04 2014

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"